Cytisine modulates chronic voluntary ethanol consumption and ethanol-induced striatal up-regulation of ΔFosB in mice

Alcohol

Volumn 47, Issue 4, 2013, Pages 299-307

  Sajja, Ravi Kiran ^a   Rahman, Shafiqur ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

FosB; Alcohol; Animal model; Cytisine; Intermittent access; Nicotinic receptor; Striatum

Indexed keywords

ALCOHOL; CYTISINE; NICOTINIC RECEPTOR; SODIUM CHLORIDE; TRANSCRIPTION FACTOR DELTA FOSB;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; BRAIN FUNCTION; BRAIN LEVEL; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; FLUID INTAKE; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; STRIATE CORTEX; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ALCOHOL DRINKING; ALKALOIDS; ANIMALS; AZOCINES; BASAL GANGLIA; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CHOICE BEHAVIOR; DRUG ADMINISTRATION SCHEDULE; DRUG PARTIAL AGONISM; ETHANOL; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-FOS; QUINOLIZINES; RECEPTORS, NICOTINIC; TIME FACTORS; UP-REGULATION; VOLITION;

ANIMALIA; MUS;

EID: 84878015097     PISSN: 07418329     EISSN: 18736823     Source Type: Journal    
DOI: 10.1016/j.alcohol.2013.02.003     Document Type: Article

References (49)

1. Bell R.L., Eiler B.J., Cook J.B., Rahman S. Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 2009, 43:581-592.
2. Breese G.R., Sinha R., Heilig M. Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacology & Therapeutics 2011, 129:149-171.
3. Carbonnelle E., Sparatore F., Canu-Boido C., Salvagno C., Baldani-Guerra B., Terstappen G., et al. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. European Journal of Pharmacology 2003, 471:85-96.
4. Chatterjee S., Bartlett S.E. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS & Neurological Disorders - Drug Targets 2010, 9:60-76.
5. Chatterjee S., Steensland P., Simms J.A., Holgate J., Coe J.W., Hurst R.S., et al. Partial agonists of α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 2011, 36:603-615.
6. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry 2005, 48:3474-3477.
7. Crabbe J.C., Harkness J.H., Spence S.E., Huang L.C., Metten P. Intermittent availability of ethanol does not always lead to elevated drinking in mice. Alcohol 2012, 47:509-517.
8. El-Gundi M., George S.R., Drago J., Fletcher P.J., Fan T., Nguyen T., et al. Disruption of dopamine D1 receptor gene expression attenuates alcohol seeking behavior. European Journal of Pharmacology 1998, 353:149-158.
9. Ericson M., Löf E., Stomberg R., Söderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. Journal of Pharmacology and Experimental Therapeutics 2009, 329:225-230.
10. Franklin K.B.G., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Academic Press, Inc., New York. 3rd ed.
11. Hendrickson L.M., Zhao-Shea R., Pang X., Gardner P.D., Tapper A.R. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. Journal of Neuroscience 2010, 30:10169-10176.
12. Hendrickson L.M., Zhao-Shea R., Tapper A.R. Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berlin) 2009, 204:563-572.
13. Hwa L.S., Chu A., Levinson S.A., Kayyali T.M., DeBold J.F., Miczek K.A. Persistent escalation of alcohol drinking in C57BL/6J mice with intermittent access to 20% ethanol. Alcoholism: Clinical and Experimental Research 2011, 35:1938-1947.
14. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
15. Kuzmin A., Jerlhag E., Liljequist S., Engel J. Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berlin) 2009, 203:99-108.
16. Larsson A., Engel J.A. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neuroscience & Biobehavioral Reviews 2004, 27:713-720.
17. Li J., Cheng Y., Bian W., Liu X., Zhang C., Ye J.H. Region-specific induction of FosB/ΔFosB by voluntary alcohol intake: effects of naltrexone. Alcoholism: Clinical and Experimental Research 2010, 34:1742-1750.
18. Loi B., Lobina C., Maccioni P., Fantini N., Carai M.A., Gessa G.L., et al. Increase in alcohol intake, reduced flexibility of alcohol drinking, and evidence of signs of alcohol intoxication in Sardinian alcohol-preferring rats exposed to intermittent access to 20% ethanol. Alcoholism: Clinical and Experimental Research 2010, 34:2147-2154.
19. Marttila K., Raattamaa H., Ahtee L. Effects of chronic nicotine administration and its withdrawal on striatal FosB/DeltaFosB and c-Fos expression in rats and mice. Neuropharmacology 2006, 51:44-51.
20. McClung C.A., Ulery P.G., Perrotti L.I., Zachariou V., Berton O., Nestler E.J. DeltaFosB: a molecular switch for long-term adaptation in the brain. Molecular Brain Research 2004, 132:146-154.
21. Melendez R.I. Intermittent (every-other-day) drinking induces rapid escalation of ethanol intake and preference in adolescent and adult C57BL/6J mice. Alcoholism: Clinical and Experimental Research 2011, 35:652-658.
22. Melendez R.I., Middaugh L.D., Kalivas P.W. Development of an alcohol deprivation and escalation effect in C57BL/6J mice. Alcoholism: Clinical and Experimental Research 2006, 30:2017-2025.
23. Minuer Y.S., Somenzi O., Picciotto M.R. Cytisine, a partial agonist of high affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007, 52:1256-1262.
24. Muller D.L., Unterwald E.M. D1 dopamine receptors modulate deltaFosB induction in rat striatum after intermittent morphine administration. Journal of Pharmacology and Experimental Therapeutics 2005, 314:148-154.
25. Nestler E.J., Barrot M., Self D.W. DeltaFosB: a sustained molecular switch for addiction. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:11042-11046.
26. Nye H.E., Hope B.T., Kelz M.B., Iadarola M., Nestler E.J. Pharmacological studies of the regulation of chronic FOS-related antigen induction by cocaine in the striatum and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 1995, 275:1671-1680.
27. O'Connor E.C., Parker D., Rollema H., Mead A.N. The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berlin) 2010, 208:365-376.
28. Papke R.L., Heinemann S.F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Molecular Pharmacology 1994, 45:142-149.
29. Papke R.L., Wecker L., Stitzel J.A. Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. Journal of Pharmacology and Experimental Therapeutics 2010, 33:501-518.
30. Perrotti L.I., Weaver R.R., Robison B., Renthal W., Maze I., Yazdani S., et al. Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse 2008, 62:358-369.
31. Rahman S. Brain nicotinic receptors as emerging targets for drug addiction: neurobiology to translational research. Progress in Molecular Biology and Translational Science 2011, 98:349-365.
32. Rahman S., Prendergast M.A. Cholinergic receptor system as a target for treating alcohol abuse and dependence. Recent Patents on CNS Drug Discovery 2012, 7:145-150.
33. Rezvani A.H., Slade S., Wells C., Petro A., Lumeng L., Li T.K., et al. Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berlin) 2010, 211:161-174.
34. Rhodes J.S., Best K., Belknap J.K., Finn D.A., Crabbe J.C. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiology & Behavior 2005, 84:53-63.
35. Robison A.J., Nestler E.J. Transcriptional and epigenetic mechanisms of addiction. Nature Reviews Neuroscience 2011, 12:623-637.
36. Rollema H., Guanowsky V., Mineur Y.S., Shrikhande A., Coe J.W., Seymour P.A., et al. Varenicline has anti-depressant like activity in the forced swim test and augments sertraline's effect. European Journal of Pharmacology 2009, 605:114-116.
37. Rollema H., Shrikhande A., Ward K.M., Tingley F.D., Coe J.W., O'Neill B.T., et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. British Journal of Pharmacology 2010, 160:334-345.
38. Sajja R.K., Dwivedi C., Rahman S. Nicotinic ligands modulate ethanol-induced dopamine function in mice. Pharmacology 2010, 86:168-173.
39. Sajja R.K., Rahman S. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011, 35:257-264.
40. Sajja R.K., Rahman S. Neuronal nicotinic receptor ligands modulate chronic nicotine-induced ethanol consumption in C57BL/6J mice. Pharmacology Biochemistry & Behavior 2012, 102:36-43.
41. Sanchis-Segura C., Borchardt T., Vengeliene V., Zghoul T., Bachteler D., Gass P., et al. Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behavior and relapse. Journal of Neuroscience 2006, 26:1231-1238.
42. Slater Y.E., Houlihan L.M., Maskell P.D., Exley R., Bermúdez I., Lukas R.J., et al. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 2003, 44:503-515.
43. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiological Reviews 2009, 89:649-705.
44. Steensland P., Simms J.A., Holgate J., Richards J.K., Bartlett S.E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12518-12523.
45. Turner J.R., Castellano L.M., Blendy J.A. Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behaviors. Journal of Pharmacology and Experimental Therapeutics 2010, 334:665-672.
46. Tutka P., Zatoński W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacological Reports 2006, 58:777-798.
47. Vanderschuren L.J., Di Ciano P., Everitt B.J. Involvement of the dorsal striatum in cue-controlled cocaine seeking. Journal of Neuroscience 2005, 25:8665-8670.
48. Vilpoux C., Warnault V., Pierrefiche O., Daoust M., Naassila M. Ethanol-sensitive brain regions in rat and mouse: a cartographic review, using immediate early gene expression. Alcoholism: Clinical and Experimental Research 2009, 33:945-969.
49. Wallace D.L., Vialou V., Rios L., Carle-Florence T.L., Chakravarty S., Kumar A., et al. The influence of DeltaFosB in the nucleus accumbens on natural reward-related behavior. Journal of Neuroscience 2008, 28:10272-10277.